Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27;77(5):1385-1395.
doi: 10.1093/jac/dkac056.

HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana

Ontlametse T Bareng  1   2 , Sikhulile Moyo  1   3 , Melissa Zahralban-Steele  3 , Dorcas Maruapula  1   4 , Tsotlhe Ditlhako  1 , Baitshepi Mokaleng  1   2 , Patrick Mokgethi  1 , Wonderful T Choga  1   5 , Natasha O Moraka  1   6 , Molly Pretorius-Holme  3 , Madisa O Mine  7 , Elliot Raizes  8 , Kesaobaka Molebatsi  1   9 , Modisa S Motswaledi  2 , Irene Gobe  2 , Terence Mohammed  1 , Tendani Gaolathe  1 , Roger Shapiro  1   3 , Mompati Mmalane  1   3 , Joseph M Makhema  1   3 , Shahin Lockman  1   3   10 , Max Essex  1   3 , Vlad Novitsky  1 , Simani Gaseitsiwe  1   3
Affiliations

HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana

Ontlametse T Bareng et al. J Antimicrob Chemother. .

Abstract

Objectives: To assess whether a single instance of low-level viraemia (LLV) is associated with the presence of drug resistance mutations (DRMs) and predicts subsequent virological failure (VF) in adults receiving ART in 30 communities participating in the Botswana Combination Prevention Project.

Methods: A total of 6078 HIV-1 C pol sequences were generated and analysed using the Stanford HIV drug resistance database. LLV was defined as plasma VL = 51-999 copies/mL and VF was defined as plasma VL ≥ 1000 copies/mL.

Results: Among 6078 people with HIV (PWH), 4443 (73%) were on ART for at least 6 months. Of the 332 persons on ART with VL > 50 copies/mL, 175 (4%) had VL ≥ 1000 copies/mL and 157 (4%) had LLV at baseline. The prevalence of any DRM was 57 (36%) and 78 (45%) in persons with LLV and VL ≥ 1000 copies/mL, respectively. Major DRMs were found in 31 (20%) with LLV and 53 (30%) with VL ≥ 1000 copies/mL (P = 0.04). Among the 135 PWH with at least one DRM, 17% had NRTI-, 35% NNRTI-, 6% PI- and 3% INSTI-associated mutations. Among the 3596 participants who were followed up, 1709 (48%) were on ART for ≥6 months at entry and had at least one subsequent VL measurement (median 29 months), 43 (3%) of whom had LLV. The OR of experiencing VF in persons with LLV at entry was 36-fold higher than in the virally suppressed group.

Conclusions: A single LLV measurement while on ART strongly predicted the risk of future VF, suggesting the use of VL > 50 copies/mL as an indication for more intensive adherence support with more frequent VL monitoring.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart showing how sequences were selected for drug resistance analysis. QC, quality control (not meeting any of inclusion criteria).
Figure 2.
Figure 2.
Flow chart showing how participants were selected for analysis of association of LLV at study entry with subsequent VF during the study follow-up.
Figure 3.
Figure 3.
DRMs in adults on ART (N = 332) with detectable plasma HIV-1 RNA > 50 copies/mL, stratified by VL groups and drug classes (including only DRMs with an overall prevalence of >2%). ARV, antiretroviral. Note that prevalence of all INSTI-associated mutations was less than 2%. **Statistically higher compared with the whole LLV group (P = 0.01).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tobin NH, Learn GH, Holte SE et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79: 9625–34. - PMC - PubMed
    1. WHO . Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017. https://www.who.int/publications/i/item/9789241550062. - PubMed
    1. Department of Human Health Services . Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Ad....
    1. European AIDS Clinical Society . EACS Guidelines. 2018. https://www.eacsociety.org/media/2018_guidelines-9.1-english.pdf.
    1. Botswana Ministry of Health . Botswana Integrated HIV Clinical Care Guidelines. 2016. https://www.childrenandaids.org/sites/default/files/2017-04/Botswana_Int....

Publication types

Substances